Showing 3651-3660 of 7318 results for "".
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Review: Gut Microbiota Dysbiosis Linked With AD, Psoriasis, and HShttps://practicaldermatology.com/news/review-gut-microbiota-linked-with-dysbiosis-with-ad-psoriasis-and-hs/2485997/A new systematic review suggests that alterations in gut microbial composition may contribute to atopic dermatitis (AD), psoriasis, and hidradeni
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Study: Tumor Location and Histologic Features Linked to Melanoma Recurrencehttps://practicaldermatology.com/news/study-tumor-location-and-histologic-features-linked-to-melanoma-recurrence/2485922/In patients with stage I–II melanoma, tumor location and histopathologic features were linked with recurrence risk beyond traditional factors such as ulceration and tumor thickness, according to a new study. Investigators exa
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Hair Prosthetic Injuries Disproportionately Affect Women in US Emergency Departmentshttps://practicaldermatology.com/news/hair-prosthetic-injuries-disproportionately-affect-women-in-us-emergency-departments/2485826/A recent analysis of the National Electronic Injury Surveillance System (NEISS) looking at hair prosthetic–related injuries presenting to US emergency departments (EDs) between 2013 and 2022 suggested these injuries disproportionately affect women.
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat